1. Home
  2. ALT vs PSNYW Comparison

ALT vs PSNYW Comparison

Compare ALT & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • PSNYW
  • Stock Information
  • Founded
  • ALT 1997
  • PSNYW 2017
  • Country
  • ALT United States
  • PSNYW Sweden
  • Employees
  • ALT N/A
  • PSNYW 2547
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • PSNYW Auto Manufacturing
  • Sector
  • ALT Health Care
  • PSNYW Consumer Discretionary
  • Exchange
  • ALT Nasdaq
  • PSNYW Nasdaq
  • Market Cap
  • ALT 292.0M
  • PSNYW 625.2M
  • IPO Year
  • ALT N/A
  • PSNYW N/A
  • Fundamental
  • Price
  • ALT $3.83
  • PSNYW $0.30
  • Analyst Decision
  • ALT Strong Buy
  • PSNYW
  • Analyst Count
  • ALT 6
  • PSNYW 0
  • Target Price
  • ALT $17.40
  • PSNYW N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • PSNYW 43.4K
  • Earning Date
  • ALT 08-12-2025
  • PSNYW 03-06-2025
  • Dividend Yield
  • ALT N/A
  • PSNYW N/A
  • EPS Growth
  • ALT N/A
  • PSNYW N/A
  • EPS
  • ALT N/A
  • PSNYW N/A
  • Revenue
  • ALT $20,000.00
  • PSNYW $2,034,261,000.00
  • Revenue This Year
  • ALT N/A
  • PSNYW N/A
  • Revenue Next Year
  • ALT $761,880.20
  • PSNYW $79.49
  • P/E Ratio
  • ALT N/A
  • PSNYW N/A
  • Revenue Growth
  • ALT N/A
  • PSNYW N/A
  • 52 Week Low
  • ALT $2.90
  • PSNYW $0.09
  • 52 Week High
  • ALT $11.16
  • PSNYW $0.61
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • PSNYW 56.04
  • Support Level
  • ALT $3.35
  • PSNYW $0.16
  • Resistance Level
  • ALT $3.66
  • PSNYW $0.80
  • Average True Range (ATR)
  • ALT 0.19
  • PSNYW 0.06
  • MACD
  • ALT 0.07
  • PSNYW 0.02
  • Stochastic Oscillator
  • ALT 86.18
  • PSNYW 15.62

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.

Share on Social Networks: